GlassScriptPhysician profile
Anna Jane Smugala
NPI 1528790276
$2,403.67
in general payments reported to CMS, 2019-2025
24 companies · $627 in 2025
The $627 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,777 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840 · Travel and Lodging: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.63 |
| Travel and Lodging | $564.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,307.49 | 2024-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $189.98 | 2024-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $91.28 | 2024-2025 | Orgovyx, Gemtesa |
| Profound Medical Corp. | $88.65 | 2025 | Tulsa-Pro |
| Procept Biorobotics Corporation | $85.91 | 2025 | |
| Progenics Pharmaceuticals, INC. | $71.67 | 2024-2025 | |
| Astellas Pharma US INC | $62.84 | 2024-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $59.19 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $48.76 | 2024-2025 | Welireg, Keytruda |
| Blue Earth Diagnostics | $46.81 | 2024-2025 | Posluma |
| Tolmar, INC. | $42.27 | 2024-2025 | Jatenzo, Eligard |
| Olympus America INC. | $42.26 | 2024 | Bovie, Uretero-Reno Videoscope, Itind System |
| C. R. Bard, INC. & Subsidiaries | $41.22 | 2025 | Bard Urinary Drainage Bag |
| Novartis Pharmaceuticals Corporation | $41.03 | 2024 | |
| Endo USA, INC. | $28.80 | 2025 | Xiaflex, Aveed |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $23.20 | 2025 | Provenge |
| Immunitybio, INC. | $20.79 | 2024 | |
| Laborie Medical Technologies Corp. | $20.22 | 2024 | Endosheath Technology |
| Alnylam Pharmaceuticals INC. | $16.84 | 2024 | Oxlumo |
| Koelis INC. | $15.73 | 2024 | |
| Boston Scientific Corporation | $15.08 | 2025 | Axonics |
| Pfizer INC. | $14.82 | 2024 | |
| Ferring Pharmaceuticals INC. | $14.53 | 2024 | Adstiladrin |
| Abbvie INC. | $14.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Smugala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.